Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing adoption of advanced skin care procedures
3.2.1.2 Increasing prevalence of pigmentation disorders
3.2.1.3 Growing expenditure on dermatological treatments
3.2.1.4 Rising awareness regarding skin health among younger population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of cosmetic procedures
3.2.2.2 Lack of reimbursement policies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Drugs
5.2.1 By type
5.2.1.1 Corticosteroids
5.2.1.2 Melanocyte-stimulating hormone
5.2.1.3 Other drugs
5.2.2 By route of administration
5.2.2.1 Oral
5.2.2.2 Topical
5.2.2.3 Other routes of administrations
5.2.3 By distribution channel
5.2.3.1 Hospital pharmacies
5.2.3.2 Retail pharmacies
5.2.3.3 Online pharmacies
5.3 Procedures
5.3.1 By type
5.3.1.1 Laser treatment
5.3.1.2 Phototherapy
5.3.1.3 Dermabrasion
5.3.1.4 Other procedures
5.3.2 By end-user
5.3.2.1 Hospitals
5.3.2.2 Dermatology clinics
5.3.2.3 Aesthetic centers
5.3.2.4 Other end-users
Chapter 6 Market Estimates and Forecast, By Type of Disorder, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hypopigmentation
6.2.1 Vitiligo
6.2.2 Albinism
6.2.3 Other hypopigmentations
6.3 Hyperpigmentation
6.3.1 Melasma
6.3.2 Lentigines
6.3.3 Post-inflammatory hyperpigmentation (PIH)
6.3.4 Other hyperpigmentations
Chapter 7 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Rest of Latin America
7.6 Middle East and Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 AbbVie Inc.
8.2 Candela Corporation
8.3 Cipher Pharmaceuticals Inc.
8.4 Galderma
8.5 GSK plc
8.6 Incyte
8.7 L'Oréal Paris
8.8 Novartis AG
8.9 Pfizer Inc.
8.10 Pierre Fabre group
8.11 Shiseido Company Limited
